DermBiont

Skin microbiome therapeutics platform to treat and prevent skin diseases.

Launch date

2017

Employees

Market cap

Enterprise valuation

€127m (Public information from Oct 2023)

Cambridge Massachusetts (HQ)

Date	Investors	Amount	Round
-	Start Capital Joyance Partners Alchimia Investments	N/A	-
Aug 2018	N/A	N/A	Series A
Jun 2019	Toba Capital Viking Global Investors Zola Global	$8.0m	Series A
Feb 2020	N/A	$2.9m	Debt
Oct 2020	N/A	$7.2m	Early VC
Feb 2021	N/A	$6.6m	Debt
Dec 2021	Toba Capital Olive Tree Capital Viking Global Investors Civilization Ventures Nan Fung Life Sciences	$28.0m	Series A
Sep 2022*	N/A	$2.5m	Debt
Mar 2023*	N/A	$4.7m	Debt
Oct 2023*	Olive Tree Capital Viking Global Investors Civilization Ventures Double Point Ventures	$27.1m Valuation: $140m	Series B
Oct 2023*	N/A	$8.1m	Convertible
Total Funding		€71.3m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by DermBiont Dec 2021

Recent News about DermBiont